Lupin Pharmaceuticals Inc. has recalled 32,136 bottles of Rifampin Capsules USP (150mg and 300mg), a prescription antibiotic used to treat tuberculosis and other bacterial infections. The medication is being recalled because it may be subpotent and failed testing for impurities and degradation. The recall affects 30-count bottles distributed to 32 wholesale accounts and 156 distribution sites. No incidents or injuries have been reported to date.
Subpotent medication may fail to effectively treat the underlying bacterial infection, which could lead to treatment failure or the development of drug-resistant bacteria. Additionally, failed impurity testing indicates the presence of unintended substances that could pose health risks to patients.
You have 2 options:
Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland; Manufactured by: Lupin Limited, India.
Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland; Manufactured by: Lupin Limited, India.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.